Ensysce Biosciences, Inc. financial data

Symbol
ENSC on Nasdaq, ENSCW on OTC
Location
7946 IVanhoe Avenue, Suite 201, La Jolla, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 264 % +60.9%
Debt-to-equity 53.2 % -50.2%
Operating Margin -110 % +80.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.41M shares -80.8%
Common Stock, Shares, Outstanding 1.64M shares -77.6%
Entity Public Float 4M USD -13%
Common Stock, Value, Issued 165 USD -77.5%
Weighted Average Number of Shares Outstanding, Basic 1.4M shares +269%
Weighted Average Number of Shares Outstanding, Diluted 1.4M shares +269%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 6.22M USD +256%
Research and Development Expense 8.33M USD +26.7%
General and Administrative Expense 4.75M USD -8.18%
Operating Income (Loss) -6.85M USD +31.5%
Nonoperating Income (Expense) 38.7K USD
Earnings Per Share, Basic -5 USD/shares +94%
Earnings Per Share, Diluted -5 USD/shares +94%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.05M USD -10.3%
Other Assets, Current 223K USD +773%
Assets, Current 4.4M USD -6.3%
Other Assets, Noncurrent 211K USD -44.1%
Assets 4.61M USD -9.11%
Accounts Payable, Current 615K USD -37.3%
Liabilities, Current 1.76M USD +7.64%
Other Liabilities, Noncurrent 130K USD
Liabilities 1.89M USD +14.4%
Retained Earnings (Accumulated Deficit) -131M USD -5.47%
Stockholders' Equity Attributable to Parent 3.05M USD -18.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 2.72M USD -20.5%
Liabilities and Equity 4.61M USD -9.11%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.71M USD +49.9%
Net Cash Provided by (Used in) Financing Activities 1.26M USD -77.9%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 1.64M shares -77.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -450K USD -120%
Deferred Tax Assets, Valuation Allowance 40.4M USD +5.04%
Deferred Tax Assets, Gross 40.4M USD +5.04%
Depreciation 0 USD
Operating Lease, Liability, Current 2.73K USD -92.3%
Deferred Tax Assets, Operating Loss Carryforwards 29.7M USD +4.36%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1.5M shares 0%
Unrecognized Tax Benefits 1.83M USD +8.4%
Operating Lease, Payments 20.7K USD -9%
Additional Paid in Capital 135M USD +4.76%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 1.25M USD +83271%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%